ATLANTA, GA – – (Newsfile Corp. – January 25, 2021) – – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR) securities between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing and controls (“CMC”) matters; (2) the Company’s IND submission for VY-HTT01 was therefore deficient; (3) the Company had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you purchased shares of Voyager securities between June 1, 2017 and November 9, 2020 and suffered significant losses on that investment, you are encouraged to contact Marshall P. Dees, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, by toll-free telephone at (888) 508-6832 or through www.holzerlaw.com to discuss your legal rights.